As IL-23 p19 subunit inhibitors are a fairly new addition to the treatment of CD, with the first study being published in 2021, research comparing the efficacy and safety profile of these drugs to other biological agents in CD treatment is scarce. This evidence concerns the gene IL23A and Cowden disease.